


PHARMACEUTICAL 2022



CHIMERIX INC Rank 457 of 475







PHARMACEUTICAL 2022

CHIMERIX INC Rank 457 of 475



The relative strengths and weaknesses of CHIMERIX INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CHIMERIX INC compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 113% points. The greatest weakness of CHIMERIX INC is the variable Net Income, reducing the Economic Capital Ratio by 552% points.

The company's Economic Capital Ratio, given in the ranking table, is -946%, being 670% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	95,805
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	29,896
Liabilities, Non-Current	2,392
Other Assets	4,482
Other Compr. Net Income	-21
Other Expenses	82,890
Other Liabilities	0
Other Net Income	164
Property and Equipment	253
Research and Development	73,817
Revenues	1,979
Selling, General and Administrative Expense	18,672

Output Variable	Value in 1000 USD
Assets	100,540
Liabilities	32,288
Expenses	175,379
Stockholders Equity	68,252
Net Income	-173,236
Comprehensive Net Income	-173,246
Economic Capital Ratio	-946%

